USD 5.1 billion
Report ID: SQSG35H2013 | Region: Global | Published Date: November, 2022 | Pages: 165
Global DNA Sequencing Market Size was valued at USD 5.1 billion in 2021, and it is expected to reach a value of USD 29.89 billion by 2028, at a CAGR of 17.9% over the forecast period (2022-2028).
The discovery of DNA variants has been made possible by quick developments in bioinformatics and sequencing technologies. These developments also identify variations linked to a higher risk of disease. The efficacy of DNA sequencing in clinical diagnosis applications is increased by the widespread use of Next-generation sequencing (NGS) and whole-genome sequencing (WGS), which allow several genes to be examined simultaneously on a single diagnostic platform. The development of pharmacological treatments for cancer is accelerated by personalised targeted sequencing of tumours, which also discovers cancer targets or pathways. The introduction of large-scale initiatives utilising NGS techniques produces fresh fundamental understanding of oncology precision therapy.
In December 2021, CVS Health unveiled Transform Oncology Care, a precision medicine initiative that makes use of genetic technologies to provide individualised cancer treatment regimens. The desire for these technologies in large-scale, rapid genome sequencing initiatives to monitor the viral propagation and inform future treatments has been driven by an exponential increase in COVID-19 patients. In collaboration with Illumina, the National Health Service of the UK, Genomics England, and Genetics of Mortality in Critical Care will provide whole-genome sequences of 35,000 UK residents who have COVID-19 in May 2021. This increases the need for DNA sequencing in the diagnosis of COVID-19.
DNA sequencing, a highly accurate and high-throughput method utilised for a range of applications including de novo assembly, WGS, and DNA resequencing, has caused a paradigm change in proteomic and genomic research. As a result, this technology is easily used for research studies in many academic research centres. At the Whitehead Institute for Biomedical Research in Massachusetts, the US, Illumina installed the NovaSeq 6000 Sequencing System in June 2021. The market for DNA sequencing is driven by initiatives done by the Centers for Medicare and Medicaid Services (CMS), Association for Molecular Pathology, as well as private payers like Blue Cross Blue Shield and Aetna to increase the clinical utilisation of sequencing technology. For instance, in January 2021, CMS increased the coverage of NGS-based diagnostic tests for those with ovarian and breast cancer, giving patients greater options to tailor their cancer treatment.
Global Market Size
USD 5.1 billion
To get more reports on the above market click here to Buy The Report
Global DNA Sequencing Market is segmented based on Product, Application, Technology, End User, and Region. Based on Product the market is further sub segmented into Consumable, Instrument, and Service. Based on Application the market is further sub-segmented into Biomarkers and Cancer, Diagnostics, Reproductive Health, Personalized Medicine, Forensics, and Others. Based on Technology the market is further sub segmented into Sequencing by Synthesis, Ion Semiconductor Sequencing, Sequencing by Ligation, Pyrosequencing, Single Molecule Real-time Sequencing, Chain Termination Sequencing, and Nanopore Sequencing. Based on End User the market is further sub segmented into Academic & Government Research Institutes, Pharmaceutical Companies, Biotechnology Companies, and Hospitals & Clinics. Based on Region, the market is further sub-segments into North America, Europe, Asia Pacific, Latin America, and MEA .
Analysis by Product
With a revenue share of 43.3%, consumables dominated the DNA sequencing market in 2021. A bigger part of the segment is attributed to the broad availability of reagents and kits to address all stages of library assembly, including DNA fragmentation, enrichment, adaptor ligation, amplification, and quality control. The majority of these programs support low-input and formalin-fixed specimens and have streamlined and simplified processes, ready-to-use components, and components.
The market for DNA sequencing is driven in part by the ongoing development of reagents and kits to make WGS more available and inexpensive. For instance, Illumina Inc. introduced the NovaSeq 6000 v1.5 Reagent Kit in August 2021, making the WGS technology more affordable and available to all laboratories and lowering the price to sequence a human genome to US$ 600. These novel kits are compatible with liquid biopsy, single-cell genomics, and WGS methods.
Numerous sequencing difficulties, like erratic base distributions and numerous hairpin loops, are resolved by sequencing services. The service providers' streamlined technology platforms and proprietary reagents guarantee very accurate performance, and their highly skilled staff helps with any unique needs of customers. They provide quick turnaround times, excellent customer service, and technical support, which is expected to propel the services sector at the market's quickest CAGR.
Analysis by Technology
DNA sequencing was dominated by next-generation sequencing in 2021, which generated 58.6% of the market's total revenue. Genome sequencing is now quicker, more accessible, and more precise because of these revolutionary advancements in technology and the falling cost of sequencing. Additionally, the use of NGS technology for routine clinical diagnostic tests is growing, especially in light of the COVID-19 infection pandemic, which benefits the segment's revenue share.
The FDA has granted Illumina's COVIDSeq Test, which is designed to sequence the entire genome of the brand-new SARS-CoV-2 virus, an Emergency Use Authorization (EUA). This test can process over 3,000 samples and provides findings in less than 24 hours thanks to Illumina's high-throughput NovaSeq 6000 technology. The Helix COVID-19 NGS Test for the identification of SARS-CoV-2 infection was also granted EUA by Helix OpCo LLC in April 2021. The market for DNA sequencing is expected to experience a significant CAGR throughout the projection period for third-generation sequencing techniques like Nanopore and Single-Molecule Real-Time sequencing. This technology fixes the problems with second-generation methods since it allows for quick and simple sample preparation without the requirement for PCR amplification. Additionally, it produces lengthy reads longer than several kilobases allowing the identification of repeated regions in complicated genomes.
Analysis by Workflow
The primary phase of the entire workflow, sequencing, had the highest revenue share (52.8%) in the DNA sequencing market in 2021. This process makes it possible to profile the genome's sequence and analyse DNA-protein interactions. It contributes more because it is a crucial component of the complete DNA sequencing workflow in research and discovery activities. The speed with which sequencers can produce a lot of data in a short amount of time advances our understanding of human health and illness treatments.
Additionally, the development of this workflow brought about by Paired-End (PE) sequencing contributes to segment growth in the DNA sequencing market. PE sequencing enables the DNA fragments to sequence from both ends, resulting in twice as many readings in a comparable amount of time. With single-read data, it is impossible to accurately align reads or discover indels in sequences that have been aligned as read pairs. During the analysis period, it is expected that the workflow for data processing will rise significantly. Commercial cloud computing systems have advanced quickly in recent years. This expands the number of data centres, adds services, lowers costs, and makes a sizable profit to support the operation of current genomics software. These platforms have led to technological developments in data integration tools that facilitate the processing and interpretation of enormous amounts of sequencing data.
Analysis by Application
Oncology dominated the DNA sequencing market in terms of revenue in 2021, accounting for the highest revenue share of 24.4 %. Technology has enormous potential for clinical research and the creation of cancer treatments and diagnostics. Recent advancements in NGS technology have shown its potential as a high-throughput, low-cost method for identifying and characterising therapeutically useful genetic variations across a wide range of genes quickly and in a single test.
Furthermore, companies and physicians alike widely acknowledge the significance of these technologies in companion diagnostics and precision medicine. Regarding this, the FDA approved the first liquid biopsy companion diagnostic that uses NGS technology to direct cancer treatment in August 2021. A number of biomarkers of genomic abnormalities in the tumour can be simultaneously mapped using the Guardant360 CDx assay, which encourages less invasive testing. The market for DNA sequencing is predicted to experience the fastest CAGR in consumer genomics during the forecast period. This can be due to the quick growth of personal health awareness, genealogy, and paternity testing. Along with the rise of additional small-mid sized businesses active in the consumer genomics market, biotechnology firms like AncestryDNA, Helix Opto LLC, and 23andMe are involved in the delivery of the "Personal Genome Service."
Analysis by End Use
Due to the widespread use of Sanger technology and NGS in academic and institutional research initiatives, the academic research segment dominated the market for DNA sequencing in 2021 with a revenue share of 55.4%. A boost in funding and investment programmes also increases the demand for DNA sequencing products in these organisations, increasing their revenue share.
For instance, the Broad Institute, Harvard University, and DNA Script received US$ 23.0 million from the Intelligence Advanced Research Projects Activity in January 2021. For more than four years, the organisations have been collaborating to investigate the viability of fusing NGS and enzymatic DNA synthesis technology into a single device. Additionally, this collaboration intends to collaborate with Illumina to make use of its sequencing-by-synthesis technology. The clinical research market is expected to expand significantly because of a rise in the incorporation of NGS products and services in numerous clinical laboratories as a result of numerous strategic collaborations between clinical laboratories and businesses. In order to expand its NGS-based clinical services, Otogenetics Corporation, a high throughput NGS clinical laboratory, inked a contract with Swift Biosciences, Inc. for the delivery of Swift 2S Turbo DNA Library Kits.
To get detailed analysis on other segments, Request For Sample Report
With a revenue share of 44.3 % in 2021, North America dominated the market for DNA sequencing. North America currently holds the largest market share for DNA sequencing due to ongoing technological advancements made by key players, significant R&D spending, and the availability of technologically advanced healthcare infrastructure. The development of new cancer treatments and medications is supported by a number of government programs in the United States and Canada. For instance, the BC Cancer Foundation's Personalized Onco-Genomics initiative, which is a part of the Provincial Health Services Authority in British Columbia, Canada, uses transcriptome and whole-genome analysis to identify the cancer genes and the medications that go with them. These medications have the ability to block important pathways in cancer patients. These open-source initiatives should increase the use of these technologies in the area.
The market for DNA sequencing is expected to expand at a profitable rate in Asia Pacific over the course of the forecast period. There will likely be many prospects for regional growth as a result of strategic actions taken by international companies to increase their presence in light of the substantial client base. For instance, a California-based company called GenapSys raised US$ 75 million in February 2021 to assist the global expansion of its tabletop DNA sequencer and the control of coronavirus in the area.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Speak to one of our ABIRAW analyst for your custom requirements before the purchase of this report
In 2021, the top companies in the worldwide DNA sequencing market are Illumina, Inc., Thermo Fisher Scientific, Agilent Technologies, QIAGEN, and Perkin Elmer. These businesses engage heavily in production, distribution, and complete quality control in order to expand their portfolio while also attempting to meet the growing consumer demand. For instance, Face2Gene LABS was launched in June 2021 by PerkinElmer, Inc. and FDNA, an artificial intelligence startup, to offer genomic services in conjunction with Next-Generation Phenotyping (NGP) technologies for more precise and effective diagnosis. By providing effective genomic testing alternatives of the highest calibre, this project demonstrated Perkin Elmer's dedication to the diagnosis of patients with genetic and uncommon illnesses. The following are a few of the leading companies in the DNA sequencing market:
Top Player’s Company Profiles
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected using Primary Exploratory Research backed by the robust Secondary Desk research.
According to our analysis, the Oncology segment dominated the global DNA Sequencing Market in 2021 and is expected to maintain its dominance throughout the forecast period. In 2021, North America dominated the global DNA Sequencing Market owing to the region's highly aware and economically stable population.
|Market size value in 2021||USD 5.1 billion|
|Market size value in 2028||USD 29.89 billion|
|Forecast Unit (Value)||USD Billion|
|Regions covered||North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA)|
Free report customization with purchase. Customization includes:-
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Parent Market Analysis
KEY MARKET INSIGHTS
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
For the Global DNA Sequencing Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Global DNA Sequencing Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Global DNA Sequencing Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Global DNA Sequencing Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "
- Mr. Ali Zali, Commercial Director, ICIIC Iran.